Type a word to start your search

Loading

MAG-CBD: Towards a natural COX-2 inhibitor

For nearly 10 years, SCF Pharma has been studying the mechanisms of resolution of inflammation of omega-3 monoglycerides in preclinical models of cancer, asthma, arthritis and colitis. In all of these models, EPA monoglyceride (MAG-EPA) dramatically reduced the expression of the COX-2 enzyme in the tissue studied. Recently, SCF Pharma obtained a cannabis research license to study different cultivars of cannabis as an inhibitor of the COX-2 enzyme. The first results have shown that CBD and its acid form CBDA are able to inhibit COX-2 and that there is no more to use the complete extract for the "entourage" effect at doses. studied. CBD was formulated with MAG-EPA as the vehicle to give MAG-CBD complex. This self-emulsifying complex demonstrated excellent COX-2 enzyme inhibitory activity in a case study. We will now initiate a phase I / II clinical study to determine the possible side effects of MAG-CBD as well as preliminary COX-2 inhibition data.

Samuel Fortin

President
SCF Pharma

CRIBIQ's contribution

$ 250 000


Partners

Industrial participants :

Samuel C. Fortin Pharma Inc.